AMZNprintsminutestrendsdividendsdrawdownsP/E 28.4macronarrativesvolatilitybuybackssentiment+0.8%marginsMSFTPMI 52.1momentumdividendsflowsPMI 52.1digeststhreadsvolatilityearnings callsvolumesβ 1.24breakoutsnewsflow2s10sliquidityheadlines−1.2%breakoutsnoiseGOOGLbuybacksrevisionstrendsPMI 52.1briefstickersnoiseGDPsentimentchattertranscriptsGOOGLsentimentvolatilitybuybacksMSFTwhispersMETAsessionsyield curves13FfuturesdowngradesPMI 52.1headlinesthe tapeflowsdowngradesfutures+0.8%earnings callstranscriptsclosesgammacatalystsrevisionsvolatilitysentimentchatter+2.41%earnings callssentimentfilingstrends10y 4.21%cyclesbuybackswiresspx 0dtewhisperstickersQ3trendsnewsflowearnings callsWTI 78.2sentimentnoisethreadsrumorsnarrativesFOMCconsensusestimatesmomentumYoY +18%tickersmomentumprintsβ 1.24revisions

momentumheadlines52w hipositioning2s10sfilingstrendsprintstrendsmacrocyclesnoise2s10smacroQ3narrativesheadlinesflowscyclesnarrativesspreadstranscriptsdowngradesupgradeswhisperswhispersminutesthe tapeNDXfuturesminutesyield curves52w hithe tapeFOMCcatalystsbriefsthe tapeNVDAguidancetrends52w hidrawdowns2s10swhispersmomentumdrawdownsbuybacks

PCEliquiditysentimentbreakoutsdowngradesP/E 28.4threadsAAPLSPXvolatilityNDXflowscyclesliquidityestimatesEPS 4.12

IONS · NASDAQ · Biotechnology

Ionis Pharmaceuticals (IONS)

Develops antisense medicines through owned launches and pharmaceutical partnerships.

$45.90

After hours+0.18 (+0.39%)

At close$45.72(+1.83%)

Investors Dumped Ionis Pharmaceuticals Stock -- But Wall Street Hasn't Budged From Its Bullish Outlook
The Motley FoolSep 20
Ionis Pharmaceuticals Eyes TRYNGOLZA Growth as Pipeline Faces Cardio Setbacks
MarketBeatSep 19
Ionis Pharmaceuticals, Inc. (IONS) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript
Seeking AlphaSep 16
Ionis Pharmaceuticals, Inc. (IONS) Presents at Wells Fargo 21st Annual Healthcare Conference Transcript
Seeking AlphaSep 10Earnings
Ionis Pharmaceuticals (NASDAQ:IONS) Shares Gap Down After Analyst Downgrade
Defense WorldSep 9Price target
Ionis Pharmaceuticals, Inc. (IONS) Discusses FDA Approval and Launch Strategy for ZANVASTRO in Alexander Disease Transcript
Seeking AlphaSep 4Clinical
Ionis Pharmaceuticals Wins FDA Approval for First Alexander Disease Treatment
MarketBeatSep 4Clinical
IONS Secures FDA Nod for Rare Brain Disorder Drug Zanvastro
Zacks Investment ResearchSep 4Clinical
ZANVASTRO™ (zilganersen) approved by the FDA as the first and only disease modifying treatment for Alexander disease (AxD) in pediatric and adult patients
GuruFocusSep 3Clinical
ZANVASTRO™ (zilganersen) approved by the FDA as the first and only disease modifying treatment for Alexander disease (AxD) in pediatric and adult patients
Business WireSep 3Clinical
US FDA approves Ionis Pharma's therapy to treat rare brain disorder
ReutersSep 3Clinical
Why Is Ionis Pharmaceuticals (IONS) Up 17.2% Since Last Earnings Report?
Zacks Investment ResearchAug 28Market move
ADAR1 Capital Management LLC Acquires Shares of 166,286 Ionis Pharmaceuticals, Inc. $IONS
Defense WorldAug 26Ownership
Breakfast News: A Conversation With Ionis CEO
The Motley FoolAug 22Other
Ionis to present new data strengthening leadership in the management of severe hypertriglyceridemia (sHTG) at the European Society of Cardiology Congress 2026
Business WireAug 20Clinical
Ionis Stock Has Plunged 30%. Is It Time to Buy the Beaten-Down Stock?
The Motley FoolAug 14
IONS Investors Have Opportunity to Join Ionis Pharmaceuticals, Inc. Fraud Investigation with SBS Law
GuruFocusAug 8
IONS Investors Have Opportunity to Join Ionis Pharmaceuticals, Inc. Fraud Investigation with SBS Law
Business WireAug 8
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Ionis Pharmaceuticals, Inc. - IONS
PRNewsWireAug 6
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Ionis Pharmaceuticals, Inc. - IONS
GlobeNewsWireAug 4